Jade Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel biologic therapies for autoimmune diseases. Its lead candidate, JADE101, is a monoclonal antibody targeting APRIL for IgA nephropathy (IgAN), with a Phase 1 trial initiated in August 2025. JADE201 targets BAFF-R for multiple autoimmune disorders, and JADE301 targets an undisclosed pathway. The company focuses on improved potency, pharmacokinetics, and subcutaneous dosing convenience.
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-06 | 2025-12-31 | 0001193125-26-096550 | EDGAR | 96K words |
| 2025-03-27 | 2024-12-31 | 0001558370-25-003750 | EDGAR | 70K words |
| 2024-03-25 | 2023-12-31 | 0001798749-24-000015 | EDGAR | 85K words |
| 2023-03-29 | 2022-12-31 | 0001798749-23-000015 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001493152-22-008189 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001193125-26-341242 | EDGAR | 63K words |
| 2025-11-14 | 2025-09-30 | 0001193125-25-281525 | EDGAR | 62K words |
| 2025-08-13 | 2025-06-30 | 0001193125-25-179853 | EDGAR | 59K words |
| 2025-04-25 | 2025-03-31 | 0001558370-25-005564 | EDGAR | 42K words |
| 2024-11-12 | 2024-09-30 | 0001798749-24-000059 | EDGAR | 43K words |
| 2024-08-12 | 2024-06-30 | 0001798749-24-000049 | EDGAR | 50K words |
| 2024-05-13 | 2024-03-31 | 0001558370-24-007985 | EDGAR | 51K words |
| 2023-11-13 | 2023-09-30 | 0001798749-23-000060 | EDGAR | 53K words |
| 2023-08-14 | 2023-06-30 | 0001798749-23-000056 | EDGAR | 53K words |
| 2023-05-15 | 2023-03-31 | 0001798749-23-000039 | EDGAR | 52K words |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017586 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022598 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-10 | 0001193125-26-341229 | EDGAR | 3K words |
| 2026-04-02 | 0001193125-26-140091 | EDGAR | 1K words |
| 2026-03-06 | 0001193125-26-094967 | EDGAR | 2K words |
| 2026-01-05 | 0001193125-26-001502 | EDGAR | 2K words |
| 2025-12-15 | 0001193125-25-318436 | EDGAR | 1K words |
| 2025-11-14 | 0001193125-25-281498 | EDGAR | 19K words |
| 2025-10-07 | 0001193125-25-232562 | EDGAR | 5K words |
| 2025-09-09 | 0001193125-25-198777 | EDGAR | 1K words |
| 2025-08-13 | 0001193125-25-179828 | EDGAR | 3K words |
| 2025-07-01 | 0001193125-25-153427 | EDGAR | 1K words |
84 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001798749 |
| Ticker | JBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.jadebiosciences.com |
| Listed | 2025-04-29 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/JBIO (~200 tokens, structured JSON with cryptographic provenance)